Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

r $168,395, to $2.1 million for the six months ended June 30, 2009, compared to $2.3 million for the same period in 2008. These decreases were primarily due to a decrease in personnel related expenses through personnel reductions, a decrease in travel expenses, and a reduction in insurance premium expense. These decreases were offset by an increase in outside services related to investment banking activities and an increase in legal expenses.

Other income decreased 98%, or $55,774 to $958 for the three months ended June 30, 2009, compared to $56,732 for the comparable period in 2008 and decreased 95%, or $145,137 to $7,600 for the six months ended June 30, 2009, compared to $152,737 for the same period in 2008. These decreases were due to a decrease in interest income due to lower cash balances.

Net loss decreased 26%, or $540,603 to $1.6 million for the three months ended June 30, 2009, compared to $2.1 million for the same period in 2008 and the net loss for the six months ended June 30, 2009, decreased 15%, or $628,477 to $3.5 million, compared with a net loss of $4.1 million for the same period in 2008. These decreases were primarily due to lower operating expenses offset by lower revenues.

Liquidity and Capital Resources

We had approximately $3.1 million in cash and cash equivalents, and $473,711 in restricted cash as of June 30, 2009. Based on our current operating plan, we anticipate that our existing cash and cash equivalents, together with expected royalties from third parties, will fund our operations until late 2009, assuming we do not trigger additional obligations, including contractual severance or lease obligations and unless unforeseen events arise that negatively impact our liquidity. In the event we are unsuccessful generating additional revenues or raising additional funds, we will have to substantially reduce our operations to preserve capital or seek ban
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... June 18, 2013  Techne Corporation (NASDAQ: ... has agreed to acquire 100% ownership of Bionostics ... (Bionostics).  Bionostics is a global leader in the ... verify the proper operation of in vitro ... of care blood glucose and blood gas testing.  ...
(Date:6/18/2013)... 2013 Research and ... addition of the report " DNA Sequencing ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of human genome variations, development of sequencing ... small sequencers are described as well as ...
(Date:6/18/2013)... THE WOODLANDS, Texas , June 18, 2013 ... LXRX ), a biopharmaceutical company focused on ... that John Northcott has joined the ... strategy, and operations. Mr. Northcott brings extensive commercial ... on-market commercialization across a variety of therapeutic areas. ...
Breaking Biology Technology:Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... Oct. 10 Boston Scientific,Corporation (NYSE: BSX ... the,U.S. Food and Drug Administration (FDA) to market ... Company,plans to launch the TAXUS Liberte stent early ... the introduction of its TAXUS(R),Expresss2(TM) Atom(TM) Paclitaxel-Eluting Coronary ...
... CA, Oct. 10, 2008 Senomyx, Inc.,(Nasdaq: ... proprietary technologies,to discover and develop novel flavor ingredients ... today that Senomyx Scientific Founder,University of California, San ... Y. Tsien, Ph.D., has been awarded the Nobel,Prize ...
... RALEIGH, N.C., Oct. 10 Micell Technologies ... present "The Micell Rapid Absorption,Polymer DES System" ... Cardiovascular Therapeutics (TCT) conference in Washington,DC, on ... stent in,pre-clinical studies, utilizes a bioresorbable polymer ...
Cached Biology Technology:Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY 2
(Date:6/17/2013)... remodelers understand the concept of improving original foundations with ... in the University of Pittsburgh,s Kenneth P. Dietrich School ... materials that could make drug delivery, gas storage, and ... The findings were reported in the latest issue of ... ( JACS ). , The recent work builds upon ...
(Date:6/17/2013)... State University research associate has received a prestigious fellowship ... prevent the spread of malaria. , Bart Bryant, research ... Health,s National Research Service Award Individual Postdoctoral Fellowship, which ... Kansas State University researcher to receive the award and ... such an award. , Bryant, a university doctoral graduate ...
(Date:6/17/2013)... method of mining shale gas, is widespread across Pennsylvania, ... New research in the Annals of the New ... to biodiversity including pollution from toxic chemicals, the building ... , "Shale gas has engendered a great deal of ... but effects on biological diversity and resources have scarcely ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... Researchers at King,s College London have discovered how coral ... UV rays, leading scientists to believe these compounds could ... for humans. , The team has begun to uncover ... are produced and eventually hope to recreate them synthetically ...
... From medicine and food to energy and agriculture, ... to the challenges faced by societies in the 21st ... development of gluten-free wheat, could bring hope to those ... the world population nears seven billion people, biotechnology plays ...
... and the Child & Family Research Institute have shown that ... imprint on their sons, or daughters, genes an imprint ... are expressed later in life. The study, published online ... epigenetics the expression of genes as opposed to the ...
Cached Biology News:Tropical coral could be used to create novel sunscreens for human use, say scientists 2Tropical coral could be used to create novel sunscreens for human use, say scientists 3Parents' stress leaves lasting marks on children’s genes: UBC-CFRI research 2
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known mammal ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Molecular Imaging Systems offer an optional ... science researchers to conveniently capture and ... organs and whole animals with molecular ... of molecular signals that are generated ...
... Features hardwall acrylic panels ... frame to form a free-standing ... to Class 10/ISO 3. Optional ... and ionizers are configured to ...
Biology Products: